The Combination of Anti-Thymocyte Globulin and Basiliximab for Haploidentical Hematopoietic Stem Cell Transplantation
PDF

Keywords

Basiliximab
Anti-Thymocyte Globulin
Haploidentical Hematopoietic Stem Cell Transplantation

Categories

How to Cite

1.
Wang F, Luo Y, Zhang Y, Lou S, Zhou K, Chen S, Zeng H, Shen Y, Deng J. The Combination of Anti-Thymocyte Globulin and Basiliximab for Haploidentical Hematopoietic Stem Cell Transplantation. Integr J Med Sci [Internet]. 2021 Mar. 17 [cited 2021 Sep. 28];8. Available from: https://mediterraneanjournals.com/index.php/ijms/article/view/474

Abstract

Objectives: Identical hematopoietic stem cell transplantation (haplo-HSCT) is associated with a higher risk of graft rejection when compared to matched sibling donor transplantations. Methods: The study included 34 patients who were treated with a novel regimen combining basiliximab, Anti-thymocyte globulin (ATG) and conventional immunosuppressive in the recipients of haplo-HSCT. Results: The cumulative incidence of grade II–IV and grade III–IV aGVHD was 38.2% and 11.8%, while the rates of limited and extensive cGVHD were 17.6% and 23.5%, respectively. Laboratory evidence of CMV and EBV reactivation were found in 9 patients (26.5%) and 6 patients (18.8%), respectively. The relapse rate of haplo-HSCT was 14.7% at 1 year; and 1-year OS and DFS were achieved in 58.8% and 55.9% of the patients, respectively. Conclusions: The results suggested that basiliximab combined with low-dose ATG could be a promising treatment strategy in haplo-HSCT.

https://doi.org/10.15342/ijms.2021.474
PDF
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2021 Wang F et al.

Metrics

Metrics Loading ...